A patient on progesterone supplementation has urinary estrone‑3‑glucuronide (E1G) ~122 µg/L on cycle day 23–24 and 68 µg/L on day 25 after the LH surge; does this estrogen pattern indicate early pregnancy and what is the likelihood that she is pregnant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Estrogen Levels and Early Pregnancy Assessment

Your urinary estrone-3-glucuronide (E1G) levels of 122 µg/L on cycle days 23-24 followed by 68 µg/L on day 25 represent a substantial elevation above your baseline (6.2 µg/L) and are consistent with early pregnancy, though confirmation requires additional testing.

Understanding Your Hormone Pattern

Your E1G levels show a 20-fold increase from baseline (6.2 µg/L to 122 µg/L), which significantly exceeds the typical 5-fold increase seen during the luteal phase of non-pregnant cycles 1. This magnitude of elevation is more consistent with early pregnancy than a normal luteal phase.

Key Observations Supporting Pregnancy:

  • Sustained elevation: E1G levels of 122-129 µg/L on days 21,23, and 24 represent a sustained rise well above the typical luteal phase pattern 1
  • Baseline comparison: Your follicular phase E1G of 6.2 µg/L provides a clear reference point, making the 20-fold increase particularly significant 1
  • Pattern consistency: Despite the drop to 68 µg/L on day 25, this level remains 11-fold higher than your baseline, which is still elevated beyond typical luteal phase values 1

Progesterone Context

Your pregnanediol-3-glucuronide (PdG) levels of 20 µg/L are artificially elevated due to progesterone supplementation, making them less useful for pregnancy assessment 2. However, the sustained PdG levels confirm adequate luteal support, which is appropriate given your supplementation 2.

Likelihood of Pregnancy

The probability of pregnancy is moderate to moderately-high based on your hormone pattern, though several factors require consideration:

Favorable Indicators:

  • E1G elevation of 20-fold above baseline is substantially higher than the typical 5-fold luteal phase increase 1
  • Sustained elevation across multiple days (days 21-24) 1
  • Timing at 9-10 days post-ovulation is appropriate for early pregnancy hormone changes 2

Caveats:

  • The drop from 122 to 68 µg/L on day 25 could represent normal day-to-day variation (which can be 25-40% even when corrected for creatinine) 1 or could signal a non-viable pregnancy
  • E1G alone cannot definitively confirm pregnancy; beta-hCG testing is required for confirmation 2, 1
  • Individual variation in E1G levels during early pregnancy is substantial 3

Critical Next Steps

Obtain serum beta-hCG testing immediately to confirm pregnancy status, as urinary steroid measurements alone cannot provide definitive pregnancy confirmation 1. If beta-hCG is positive, serial measurements 48 hours apart will assess pregnancy viability better than E1G monitoring 4.

Monitoring Recommendations:

  • Continue progesterone supplementation as prescribed until pregnancy status is confirmed 4
  • If pregnancy is confirmed, progesterone supplementation typically continues until 34-37 weeks gestation 5
  • The day-to-day fluctuation in E1G (122 to 68 µg/L) is within the expected coefficient of variation and should not cause immediate alarm 1

Common Pitfall to Avoid

Do not discontinue progesterone supplementation based on E1G fluctuations alone, as progesterone support is critical during early pregnancy and should only be adjusted based on clinical assessment and beta-hCG confirmation 4, 5.

References

Research

Distinct urinary progesterone metabolite profiles during the luteal phase.

Hormone molecular biology and clinical investigation, 2023

Research

Progesterone and the luteal phase: a requisite to reproduction.

Obstetrics and gynecology clinics of North America, 2015

Guideline

Progesterone Dosing for Pregnancy with Subchorionic Hemorrhage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

I experienced a peak luteinizing hormone (LH) surge and elevated estradiol (E1G) on cycle day 13‑14, but pregnanediol‑glucuronide (PDG) stayed low; did I ovulate, when should I begin progesterone for luteal support, and how long would the oocyte have remained viable?
In a patient on progesterone supplementation, with baseline estrone‑3‑glucuronide 6.2 ng/mL on cycle day 5 and urinary estrone‑3‑glucuronide ~122 ng/mL on cycle day 23–24 (≈10 days after the LH surge), does this estrogen level indicate early pregnancy and what is the probability of being pregnant?
Is my estrone‑glucuronide (E1G) level of 43.8 µg on cycle day 20 (seven days after the LH surge) appropriate for early pregnancy while I am receiving progesterone supplementation?
Does estrone (e1g) level increase 7-10 days post peak in the luteal phase in a female patient of reproductive age, and if so, how much does it rise above baseline levels?
Why did my reproductive endocrinologist advise intercourse a day after the urinary pregnanediol-3-glucuronide rise when I already had sex 2-3 days before ovulation and am taking 200 mg progesterone daily from cycle day 15?
What criteria should a clinician and patient use to determine that therapeutic goals have been met and the client with anxiety can be discharged from active treatment?
In a pregnant patient with a positive hCG, urinalysis showing pyuria, hematuria, many squamous epithelial cells, and a urine culture indicating contamination, what is the appropriate next step?
For a 9.5 kg infant, what is the appropriate acetaminophen (Tylenol) dose in milligrams per administration?
In an end‑stage renal disease patient on intermittent hemodialysis presenting with hematuria, is ciprofloxacin appropriate and what dose regimen should be used?
How should I adjust insulin therapy for a patient taking 25 units insulin glargine (Lantus) daily with blood glucose readings in the 300‑400 mg/dL range?
How can I obtain a 2 mg/mL concentration from a 36 mg vial of retatrutide?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.